Opinion|Videos|January 24, 2025
Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL
Panelists discuss how distinct safety profiles among Bruton tyrosine kinase (BTK) inhibitors—including variations in cardiovascular effects, bleeding risk, infection susceptibility, and other adverse events—guide personalized treatment decisions in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) based on individual comorbidities and risk factors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do differences in safety profiles between BTK inhibitors influence treatment selection in R/R CLL?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
3
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
4
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
5